NEW YORK, NY / ACCESS Newswire / February 3, 2025 / The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or ...

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various ...

SEC Filings provided by EDGAR Online, Inc.

After hours: January 31 at 5:22:21 PM EST Loading Chart for SNTI ...

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to ...

SENTI-202 is under clinical development by Senti Biosciences and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia ...

Jan. 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...